Biodesix (BDSX) Accumulated Expenses (2019 - 2026)

Biodesix has reported Accumulated Expenses for 8 years, with the latest figure at $5.5 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 26.74% year-over-year to $5.5 million; the trailing twelve-month figure through Mar 2026 stood at $5.5 million (up 26.74% YoY), and the FY2025 full-year result was $11.0 million, up 9.63% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $5.5 million, down from $11.0 million in the prior quarter.
• The five-year high for Accumulated Expenses was $11.0 million in Q4 2025, with the low at $747000.0 in Q3 2025.
• Historically, Accumulated Expenses has averaged $5.4 million across 5 years, with a median of $5.5 million in 2026.
• Annual changes were most pronounced in 2024 — Accumulated Expenses jumped 923.8% — and 2025, when it slumped 91.27%.
• Biodesix's Accumulated Expenses stood at $4.7 million in 2022, then tumbled by 78.96% to $983000.0 in 2023, then jumped by 923.8% to $10.1 million in 2024, then rose by 9.63% to $11.0 million in 2025, then slumped by 49.82% to $5.5 million in 2026.
• The last three Accumulated Expenses figures came in at $5.5 million (Q1 2026), $11.0 million (Q4 2025), and $747000.0 (Q3 2025), per Business Quant data.